Harmony Biosciences Holdings Inc（HRMY）資訊與事件HRMYHarmony Biosciences Holdings Inc

Harmony Biosciences Reports Q2 Revenue of $261.28M

Reports Q2 revenue $261.28M, consensus $253.27M. "Our record second-quarter revenue reflects sustained demand for WAKIX and keeps us firmly on track to deliver over $1 billion in revenue this year. With this strong foundation, we are aggressively advancing our pipeline, with our orexin-2 agonist BP-205 as the centerpiece, that we believe can create significant long-term value for both patients and shareholders," said Jeffrey M. Dayno, MD, President and Chief Executive Officer of Harmony Biosciences. "The Phase 1 clinical PK and safety/tolerability data for BP-205 that we shared today, together with pre-clinical data demonstrating the highest potency of any orexin-2 agonist currently in the clinic, reinforce our conviction that BP-205 has the potential to be the best-in-class orexin-2 agonist with broad clinical utility across multiple CNS indications."

Harmony CFO Glenn Reicin Resigns, Stephen Mollichella Appointed Interim

Harmony also announced that its Chief Financial Officer, Glenn Reicin, has stepped down to pursue other opportunities, effective July 16, 2026. The Company appointed Stephen Mollichella, SVP and Controller, as Interim Principal Financial Officer, ensuring continuity in the Company's financial leadership as it conducts its search for a permanent CFO. Reicin's departure is not the result of any disagreement with the Company on any matter relating to its operations, policies or practices, and Harmony does not expect this transition to affect its performance or momentum in any way.

Harmony Biosciences Expects Full-Year Net Revenue of $1.0 to $1.04 Billion

"Our record quarterly results reflect the continued strength of the WAKIX franchise and sustained momentum across the business," said Jeffrey Dayno, M.D., President and Chief Executive Officer of Harmony Biosciences. "Demand remains strong, our commercial execution continues to deliver results and, based on our performance through the first half of the year, we remain confident in our ability to achieve full-year net revenue of $1.0 billion to $1.04 billion."